Prognostic role of early prostate specific antigen changes after [ 177 Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis.
Luca M GiovanellaMaria Luisa GaroMarco CuzzocreaGaetano PaoneKen HerrmannPublished in: European journal of clinical investigation (2023)
Lu]Lu-PSMA cycles, with a significantly longer OS compared to stable or increased PSA levels, respectively. Accordingly, any PSA decline after 1-2 cycles of therapy should be regarded as a favourable prognostic factor for OS.